Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.)(Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.))

概要

基本信息

药物类型

siRNA

别名-

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Matinas Biopharma Nanotechnologies, Inc.

在研机构

Matinas Biopharma Nanotechnologies, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.) 相关的专利（医药）

登录后查看更多信息

1

项与 Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.) 相关的文献（医药）

F1000Research

Novel antifungal agents in clinical trials

Review

作者: Walsh, Thomas J ; Zagaliotis, Panagiotis ; Jacobs, Samantha E

Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.

100 项与 Encochleated siRNA(Matinas Biopharma Nanotechnologies, Inc.) 相关的药物交易

登录后查看更多信息